Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sagimet BiosciencesSTU:0O2 +10.97%18 Gross-Profit-to-Asset % is 0.00% as of Mar. 2026. GuruFocus rates STU:0O2 with a GF Score™ of 18/100. The stock has 3 warning signs investors should review. Among 958 Biotechnology companies, Sagimet Biosciences ranks worse than 104384.03% on this metric.
Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Sagimet Biosciences's annualizedGross Profit for the quarter that ended in Mar. 2026 was €0.00 Mil.
Sagimet Biosciences's average Total Assets over the quarter that ended in Mar. 2026 was €96.34 Mil. Therefore, Sagimet Biosciences's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2026 was 0.00%.
Sagimet Biosciences Gross-Profit-to-Asset % Related Terms
Sagimet Biosciences Gross-Profit-to-Asset % Historical Data
* Premium members only.
The historical data trend for Sagimet Biosciences's Gross-Profit-to-Asset % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:0O2 vs CABA, OVID, QTTB: Gross-Profit-to-Asset % Comparison
For the Biotechnology subindustry, Sagimet Biosciences's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sagimet Biosciences Gross-Profit-to-Asset % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sagimet Biosciences's Gross-Profit-to-Asset % distribution charts can be found below:
* The bar in red indicates where Sagimet Biosciences's Gross-Profit-to-Asset % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Gross Profit data used here is four times the quarterly (Mar. 2026) data.
Gross-Profit-to-Asset % is displayed in the 30-year financial page.
What does a Gross-Profit-to-Asset % of 0.00% mean?
Sagimet Biosciences (STU:0O2) has a Gross-Profit-to-Asset % of 0.00% as of Mar. 2026. Gross Profit to Asset Ratio is the total gross profit divided by total assets. View historical data on Sagimet Biosciences and its competitors. According to the industry distribution chart, Sagimet Biosciences ranks #999999 out of 958 companies in the Biotechnology industry.
Is Sagimet Biosciences' Gross-Profit-to-Asset % too high?
Sagimet Biosciences' current Gross-Profit-to-Asset % is 0.00%. Based on the distribution chart, Sagimet Biosciences ranks #999999 out of 958 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Sagimet Biosciences has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Sagimet Biosciences' Gross-Profit-to-Asset % compare to CABA and OVID?
According to the Biotechnology industry distribution chart, Sagimet Biosciences ranks #999999 out of 958 companies for Gross-Profit-to-Asset %. This places Sagimet Biosciences in the lower half of its industry. The industry median Gross-Profit-to-Asset % is 11.06. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross-Profit-to-Asset % for a Biotechnology company?
The median Gross-Profit-to-Asset % among Biotechnology companies is 11.06, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a Gross-Profit-to-Asset % significantly above this median, while those in the bottom quartile fall well below. However, Gross-Profit-to-Asset % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross-Profit-to-Asset % mean?
A high Gross-Profit-to-Asset % can signal that a stock is expensive relative to its fundamentals. Gross Profit to Asset Ratio is the total gross profit divided by total assets. View historical data on Sagimet Biosciences and its competitors. For the Biotechnology industry, the median Gross-Profit-to-Asset % is 11.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sagimet Biosciences's current Gross-Profit-to-Asset % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sagimet Biosciences stock overvalued right now?
Sagimet Biosciences (STU:0O2) has a current Gross-Profit-to-Asset % of 0.00%. The current Gross-Profit-to-Asset % is 0.00%. Sagimet Biosciences' overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross-Profit-to-Asset % calculated?
Gross-Profit-to-Asset % is calculated from a company's financial statements. For Sagimet Biosciences (STU:0O2), the current Gross-Profit-to-Asset % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
18GF Score
Get the complete analysis for STU:0O2
Gross-Profit-to-Asset % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:0O2 has been successfully added to your 
